0001181431-11-032934.txt : 20110526 0001181431-11-032934.hdr.sgml : 20110526 20110526170017 ACCESSION NUMBER: 0001181431-11-032934 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110524 FILED AS OF DATE: 20110526 DATE AS OF CHANGE: 20110526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ESHELMAN FREDRIC N CENTRAL INDEX KEY: 0001033409 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34641 FILM NUMBER: 11875010 MAIL ADDRESS: STREET 1: PPD INC STREET 2: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Furiex Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001484478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271197863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3900 PARAMOUNT PARKWAY STREET 2: SUITE 150 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-456-7800 MAIL ADDRESS: STREET 1: 3900 PARAMOUNT PARKWAY STREET 2: SUITE 150 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: PPD Therapeutics, Inc. DATE OF NAME CHANGE: 20100218 4 1 rrd313378.xml FORM 4 X0303 4 2011-05-24 0 0001484478 Furiex Pharmaceuticals, Inc. FURX 0001033409 ESHELMAN FREDRIC N C/O FURIEX PHARMACEUTICALS, INC. 3900 PARAMOUNT PARKWAY, SUITE 150 MORRISVILLE NC 27560 1 0 0 0 Common Stock 2011-05-24 4 P 0 14516 14.79 A 1096203 D Common Stock 2011-05-25 4 P 0 250000 15.35 A 1346203 D Common Stock 41666 I GRAT Common Stock 938 I LLC Common Stock 140 I Spouse Stock Options (to buy) 9.11 2020-06-17 Common Stock 197627 197627 I LLC This transaction was executed in multiple trades at prices ranging from $14.18 to $15.16. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. The options were awarded on 6/17/2010 and vest and become exercisable over three years, with one-third of the Option vesting on each of the first, second and third anniversaries of the date of grant, provided that the Optionee's consulting relationship with the Company continues. /s/ Donald R. Reynolds, Attorney-in-Fact 2011-05-26